|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
134,770,000 |
Market
Cap: |
18.54(B) |
Last
Volume: |
676,634 |
Avg
Vol: |
1,177,221 |
52
Week Range: |
$120.62 - $144.92 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 724 |
Guru Rank Value : 1.3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Quest Diagnostics provides diagnostic information services. Co. is made up of two businesses: Diagnostic Information Services, which develops and delivers diagnostic information services, providing insights that allow and enable a range of customers, including patients, clinicians, hospitals, independent delivery networks (including hospital health systems), health plans, employers, accountable care organizations and direct contract entities; and Diagnostic Solutions, which includes Co.'s risk assessment services business, which provides solutions for insurers, and Co.'s healthcare information technology businesses, which provides solutions for healthcare providers.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
16,337 |
16,337 |
16,337 |
534,469 |
Total Sell Value |
$2,062,619 |
$2,062,619 |
$2,062,619 |
$75,079,355 |
Total People Sold |
3 |
3 |
3 |
6 |
Total Sell Transactions |
6 |
6 |
6 |
24 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Rusckowski Stephen H |
Chairman, CEO and President |
|
2021-03-09 |
4 |
A |
$115.42 |
$6,736,835 |
D/D |
58,368 |
310,314 |
|
- |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2021-03-09 |
4 |
D |
$115.42 |
$711,564 |
D/D |
(6,165) |
30,250 |
|
- |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2021-03-09 |
4 |
A |
$115.42 |
$1,521,351 |
D/D |
13,181 |
36,394 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2021-03-09 |
4 |
D |
$115.42 |
$584,718 |
D/D |
(5,066) |
77,265 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2021-03-09 |
4 |
A |
$115.42 |
$1,304,131 |
D/D |
11,299 |
82,331 |
|
- |
|
Davis J. E. |
EVP, General Diagnostics |
|
2021-03-09 |
4 |
D |
$115.42 |
$961,910 |
D/D |
(8,334) |
49,931 |
|
- |
|
Davis J. E. |
EVP, General Diagnostics |
|
2021-03-09 |
4 |
A |
$115.42 |
$1,912,509 |
D/D |
16,570 |
58,265 |
|
- |
|
Guinan Mark |
Executive Vice President & CFO |
|
2021-03-09 |
4 |
D |
$115.42 |
$739,034 |
D/D |
(6,403) |
88,792 |
|
- |
|
Guinan Mark |
Executive Vice President & CFO |
|
2021-03-09 |
4 |
A |
$115.42 |
$1,999,305 |
D/D |
17,322 |
95,195 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2021-02-25 |
4 |
AS |
$115.49 |
$92,507 |
D/D |
(801) |
40,152 |
|
17% |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2021-02-24 |
4 |
D |
$121.19 |
$74,047 |
D/D |
(611) |
23,213 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2021-02-24 |
4 |
D |
$121.19 |
$63,504 |
D/D |
(524) |
71,032 |
|
- |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2021-02-24 |
4 |
D |
$121.19 |
$402,230 |
D/D |
(3,319) |
251,946 |
|
- |
|
Deppe Michael J |
VP, Corp. Controller & CAO |
|
2021-02-24 |
4 |
D |
$121.19 |
$12,483 |
D/D |
(103) |
25,601 |
|
- |
|
Davis J. E. |
EVP, General Diagnostics |
|
2021-02-24 |
4 |
D |
$121.19 |
$97,679 |
D/D |
(806) |
41,695 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2021-02-24 |
4 |
AS |
$116.95 |
$138,937 |
D/D |
(1,188) |
40,953 |
|
15% |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2021-02-24 |
4 |
D |
$121.19 |
$55,141 |
D/D |
(455) |
42,141 |
|
- |
|
Guinan Mark |
Executive Vice President & CFO |
|
2021-02-24 |
4 |
D |
$121.19 |
$65,564 |
D/D |
(541) |
77,873 |
|
- |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2021-02-23 |
4 |
D |
$121.15 |
$123,210 |
D/D |
(1,017) |
23,824 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2021-02-23 |
4 |
D |
$121.15 |
$96,435 |
D/D |
(796) |
71,556 |
|
- |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2021-02-23 |
4 |
D |
$121.15 |
$488,598 |
D/D |
(4,033) |
255,265 |
|
- |
|
Deppe Michael J |
VP, Corp. Controller & CAO |
|
2021-02-23 |
4 |
D |
$121.15 |
$19,263 |
D/D |
(159) |
25,704 |
|
- |
|
Davis J. E. |
EVP, General Diagnostics |
|
2021-02-23 |
4 |
D |
$121.15 |
$151,438 |
D/D |
(1,250) |
42,501 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2021-02-23 |
4 |
D |
$121.15 |
$83,957 |
D/D |
(693) |
42,596 |
|
- |
|
Guinan Mark |
Executive Vice President & CFO |
|
2021-02-23 |
4 |
D |
$121.15 |
$100,555 |
D/D |
(830) |
78,414 |
|
- |
|
787 Records found
|
|
Page 10 of 32 |
|
|